Accounts & AGM

Bioventix plc (“Bioventix” or the “Company”)   Result of AGM Bioventix plc (AIM: BVXP) announces that at its Annual General Meeting held earlier today, all resolutions put to shareholders were [...]

Bioventix plc (BVXP), a UK company specialising in the development and commercial supply of high-affinity monoclonal antibodies for applications in clinical diagnostics, confirms that its Annual [...]

Director’s report and financial statements for the year ended 30th June 2022. To download this report as a PDF file click here.

Interim Report and Financial Statements for the 6 months to 31 December 2021   To download this report as a PDF file click here.

Bioventix plc (AIM: BVXP) announces that at its Annual General Meeting (“AGM”), all resolutions put to shareholders were duly passed.

Bioventix plc (BVXP), a UK company specialising in the development and commercial supply of high-affinity monoclonal antibodies for applications in clinical diagnostics, confirms that its Annual [...]

Director’s report and financial statements for the year ended 30th June 2021. To download this report as a PDF file click here

Unaudited interim results for the six months ended 31st December 2020

Director’s report and financial statements for the year ended 30th June 2020. To download this report as a PDF file click here.